| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Eleni-Marina Kalogirou, Konstantinos I Tosios, Evangelia P Piperi, Alexandra Sklavouno. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus. Oral surgery, oral medicine, oral pathology and oral radiology. vol 119. issue 1. 2015-07-14. PMID:25442249. |
mammalian targets of rapamycin inhibitors (mtor inhibitors, mtori) are indicated for the management of several cancer types, including hormone receptor--positive or her2-negative breast cancer, advanced renal cell carcinoma, advanced neuroendocrine tumors of pancreatic origin, and tuberous sclerosis complex-related tumors. |
2015-07-14 |
2023-08-13 |
Not clear |
| Kenneth Maies. Taking aim at Alzheimer's disease through the mammalian target of rapamycin. Annals of medicine. vol 46. issue 8. 2015-07-13. PMID:25105207. |
mtor modulates multi-faceted signal transduction pathways that involve phosphoinositide 3-kinase (pi 3-k), protein kinase b (akt), hamartin (tuberous sclerosis 1)/ tuberin (tuberous sclerosis 2) (tsc1/tsc2) complex, proline-rich akt substrate 40 kda (pras40), and p70 ribosomal s6 kinase (p70s6k) and can interface with the neuroprotective pathways of growth factors, sirtuins, wingless, forkhead transcription factors, and glycogen synthase kinase-3β. |
2015-07-13 |
2023-08-13 |
Not clear |
| Alexander L Fogel, Sharleen Hill, Joyce M C Ten. Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology. Journal of the American Academy of Dermatology. vol 72. issue 5. 2015-07-13. PMID:25769191. |
recent advances in the understanding of the mtor signaling pathway and its downstream effects on tumorigenesis and vascular proliferation have broadened the clinical applications of mtoris in many challenging disorders such as tuberous sclerosis complex, pachyonychia congenita, complex vascular anomalies, and inflammatory dermatoses. |
2015-07-13 |
2023-08-13 |
Not clear |
| K Zitterbar. [Subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mTOR inhibitors]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. vol 27. issue 6. 2015-06-30. PMID:25493579. |
[subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mtor inhibitors]. |
2015-06-30 |
2023-08-13 |
Not clear |
| Souheil El-Chemaly, Hilary J Goldberg, Allan R Glanvill. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation? Expert review of respiratory medicine. vol 8. issue 6. 2015-06-29. PMID:25199529. |
lymphangioleiomyomatosis (lam) is a rare cystic lung disease characterized by proliferation of smooth muscle like cells (lam cells) that have mutations in the tuberous sclerosis gene (tsc2), leading to the activation of the mammalian target of rapamycin (mtor). |
2015-06-29 |
2023-08-13 |
Not clear |
| Kazim Sahin, Brian Cross, Nurhan Sahin, Karina Ciccone, Shadeah Suleiman, Adeboye O Osunkoya, Viraj Master, Wayne Harris, Bradley Carthon, Ramzi Mohammad, Birdal Bilir, Karin Wertz, Carlos S Moreno, Cheryl L Walker, Omer Kucu. Lycopene in the prevention of renal cell cancer in the TSC2 mutant Eker rat model. Archives of biochemistry and biophysics. vol 572. 2015-06-24. PMID:25602702. |
eker rat represents a unique animal model to study rcc since these rats develop spontaneous renal tumors and leiomyoma, which may be due to tuberous sclerosis 2 (tsc2) mutation resulting in the activation of the mammalian target of rapamycin (mtor) pathway. |
2015-06-24 |
2023-08-13 |
rat |
| Christopher M Bartley, Rachel A O'Keefe, Angélique Borde. FMRP S499 is phosphorylated independent of mTORC1-S6K1 activity. PloS one. vol 9. issue 5. 2015-06-16. PMID:24806451. |
hyperactive mammalian target of rapamycin (mtor) is associated with cognitive deficits in several neurological disorders including tuberous sclerosis complex (tsc). |
2015-06-16 |
2023-08-13 |
mouse |
| Jiandong Sun, Yan Liu, Stephanie Moreno, Michel Baudry, Xiaoning B. Imbalanced mechanistic target of rapamycin C1 and C2 activity in the cerebellum of Angelman syndrome mice impairs motor function. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 35. issue 11. 2015-06-15. PMID:25788687. |
levels of tuberous sclerosis complex 2 (tsc2), a negative regulator of mtor, were increased in as mice compared with wild-type mice; however, tsc2 inhibitory phosphorylation was also increased. |
2015-06-15 |
2023-08-13 |
mouse |
| Joanna Trelinska, Iwona Dachowska, Katarzyna Kotulska, Dobromila Baranska, Wojciech Fendler, Sergiusz Jozwiak, Wojciech Mlynarsk. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis. Pediatric blood & cancer. vol 62. issue 4. 2015-06-11. PMID:25557360. |
the aim of the study was to investigate factors affecting response to everolimus, a mammalian-target-of-rapamycin (mtor) inhibitor, of subependymal giant cell astrocytomas (sega) in patients with tuberous sclerosis complex (tsc). |
2015-06-11 |
2023-08-13 |
Not clear |
| Xiang Ou, Meilian Liu, Hairong Luo, Lily Q Dong, Feng Li. Ursolic acid inhibits leucine-stimulated mTORC1 signaling by suppressing mTOR localization to lysosome. PloS one. vol 9. issue 4. 2015-06-01. PMID:24740400. |
the ua-mediated inhibition of mtorc1 is independent of akt, tuberous sclerosis complex 1/2 (tsc1/2), and ras homolog enriched in brain (rheb), suggesting that ua negatively regulates mtorc1 signaling by targeting at a site downstream of these mtor regulators. |
2015-06-01 |
2023-08-13 |
Not clear |
| Sharad Shrestha, Kai Yang, Jun Wei, Peer W F Karmaus, Geoffrey Neale, Hongbo Ch. Tsc1 promotes the differentiation of memory CD8+ T cells via orchestrating the transcriptional and metabolic programs. Proceedings of the National Academy of Sciences of the United States of America. vol 111. issue 41. 2015-04-30. PMID:25271321. |
we describe here that tuberous sclerosis 1 (tsc1), a regulator of mtor signaling, plays a crucial role in promoting the differentiation and function of memory cd8(+) t cells in response to listeria monocytogenes infection. |
2015-04-30 |
2023-08-13 |
mouse |
| Lei Liang, Xi-Ling Shou, Hai-Kang Zhao, Gu-Qun Ren, Jian-Bang Wang, Xi-Hui Wang, Wen-Ting Ai, Jackie R Maris, Lindsay K Hueckstaedt, Ai-Qun Ma, Yingmei Zhan. Antioxidant catalase rescues against high fat diet-induced cardiac dysfunction via an IKKβ-AMPK-dependent regulation of autophagy. Biochimica et biophysica acta. vol 1852. issue 2. 2015-04-17. PMID:24993069. |
high fat diet intake dampened phosphorylation of inhibitor kappa b kinase β(ikkβ), amp-activated protein kinase (ampk) and tuberous sclerosis 2 (tsc2) while promoting phosphorylation of mtor, the effects of which were ablated by catalase. |
2015-04-17 |
2023-08-13 |
mouse |
| Elizabeth Jo Coomb. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas. Journal of the American Association of Nurse Practitioners. vol 25. issue 11. 2015-04-09. PMID:24170533. |
to describe the role of mammalian target of rapamycin (mtor) inhibition in the treatment of tuberous sclerosis complex (tsc) patients with renal angiomyolipoma in relation to available clinical data and clinical practice guidance for the nurse practitioner (np). |
2015-04-09 |
2023-08-12 |
Not clear |
| Gauhar Rehman, Adeeb Shehzad, Abdul Latif Khan, Muhammad Hamayu. Role of AMP-activated protein kinase in cancer therapy. Archiv der Pharmazie. vol 347. issue 7. 2015-04-09. PMID:24677093. |
ampk has been shown to inhibit mammalian target of rapamycin (mtor) through tuberous sclerosis complex 2 (tsc2) phosphorylation and phosphatase and tensin homolog (pten), considered as central cell growth controller signals in diseases. |
2015-04-09 |
2023-08-12 |
Not clear |
| Xinxin Xiang, He Lan, Hong Tang, Fang Yuan, Yanhui Xu, Jing Zhao, Yin Li, Weizhen Zhan. Tuberous sclerosis complex 1-mechanistic target of rapamycin complex 1 signaling determines brown-to-white adipocyte phenotypic switch. Diabetes. vol 64. issue 2. 2015-03-31. PMID:25213336. |
this study explores the role of tuberous sclerosis complex 1 (tsc1)-mechanistic target of rapamycin (mtor) signaling in the conversion of brown to white adipose tissue (wat). |
2015-03-31 |
2023-08-13 |
mouse |
| Kenneth Maies. mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus. World journal of diabetes. vol 6. issue 2. 2015-03-19. PMID:25789103. |
the pathways of mtor linked to mtor complex 1, mtor complex 2, amp activated protein kinase, and the hamartin (tuberous sclerosis 1)/tuberin (tuberous sclerosis 2) complex can ultimately influence neuronal, cardiac, and vascular cell survival during oxidant stress in dm through a fine interplay between apoptosis and autophagy. |
2015-03-19 |
2023-08-13 |
Not clear |
| Longbo Zhang, Christopher M Bartley, Xuan Gong, Lawrence S Hsieh, Tiffany V Lin, David M Feliciano, Angélique Borde. MEK-ERK1/2-dependent FLNA overexpression promotes abnormal dendritic patterning in tuberous sclerosis independent of mTOR. Neuron. vol 84. issue 1. 2015-02-20. PMID:25277454. |
mek-erk1/2-dependent flna overexpression promotes abnormal dendritic patterning in tuberous sclerosis independent of mtor. |
2015-02-20 |
2023-08-13 |
mouse |
| Ning Liang, Chi Zhang, Patricia Dill, Ganna Panasyuk, Delphine Pion, Vonda Koka, Morgan Gallazzini, Eric N Olson, Hilaire Lam, Elizabeth P Henske, Zheng Dong, Udayan Apte, Nicolas Pallet, Randy L Johnson, Fabiola Terzi, David J Kwiatkowski, Jean-Yves Scoazec, Guido Martignoni, Mario Pend. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. The Journal of experimental medicine. vol 211. issue 11. 2015-02-19. PMID:25288394. |
regulation of yap by mtor and autophagy reveals a therapeutic target of tuberous sclerosis complex. |
2015-02-19 |
2023-08-13 |
mouse |
| Ning Liang, Chi Zhang, Patricia Dill, Ganna Panasyuk, Delphine Pion, Vonda Koka, Morgan Gallazzini, Eric N Olson, Hilaire Lam, Elizabeth P Henske, Zheng Dong, Udayan Apte, Nicolas Pallet, Randy L Johnson, Fabiola Terzi, David J Kwiatkowski, Jean-Yves Scoazec, Guido Martignoni, Mario Pend. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. The Journal of experimental medicine. vol 211. issue 11. 2015-02-19. PMID:25288394. |
genetic studies have shown that the tuberous sclerosis complex (tsc) 1-tsc2-mammalian target of rapamycin (mtor) and the hippo-yes-associated protein 1 (yap) pathways are master regulators of organ size, which are often involved in tumorigenesis. |
2015-02-19 |
2023-08-13 |
mouse |
| Sandrine Benhamron, Shakti P Pattanayak, Michael Berger, Boaz Tiros. mTOR activation promotes plasma cell differentiation and bypasses XBP-1 for immunoglobulin secretion. Molecular and cellular biology. vol 35. issue 1. 2015-02-12. PMID:25332234. |
the kinase mammalian target of rapamycin (mtor) promotes anabolic activities and is negatively regulated by the tuberous sclerosis complex (tsc). |
2015-02-12 |
2023-08-13 |
mouse |